Published in Obesity and Diabetes Week, August 28th, 2006
Dr Jean-Pierre Marie of the Universite Pierre et Marie Curie in Paris published a study in the British Journal of Cancer. The phase 1 study recruited 18 advanced stage acute AML patients who had previously failed other AML treatments, and found that Ceflatonin (homoharringtonine or HHT) had significant clinical benefits. Eleven of 12...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week